#Global Trends – Page 6 – HEALTHCARE INSIGHTS

Key Development New research challenges the assumption that vascular damage in Alzheimer’s disease is primarily a downstream consequence. In APOE4... Read more

Tag: #Global Trends

ASTRAZENECA PUTS $2 BILLION BEHIND SUMMIT: THE PD-1×VEGF RACE IS SHIFTING FROM “WHO HAS THE BEST DRUG?” TO “WHO BUILDS THE BEST COMBINATION BACKBONE?”

AMT-130 LOSES STATISTICAL SIGNIFICANCE AT FOUR YEARS: HUNTINGTON’S GENE THERAPY IS ENTERING A HARDER TEST – NOT SIMPLY “FAILING”

ROCHE DROPS EMUGROBART: OBESITY COMPETITION IS SHIFTING FROM “MORE WEIGHT LOSS” TO “BETTER WEIGHT LOSS”

NOVO PUTS UP TO $2.6 BILLION BEHIND HRS-1596: THE OBESITY PILL RACE IS MOVING FROM “ONCE DAILY” TOWARD “ONCE WEEKLY”

ORPATHYS + TAGRISSO FILED WITH FDA: ASTRAZENECA IS TURNING EGFR RESISTANCE INTO A NEW BIOMARKER-DEFINED MARKET

BRELOVITUG WINS PHASE 3: THE HDV RACE IS SHIFTING FROM “HAVING A TREATMENT” TO ACHIEVING DEEPER, MORE DURABLE VIRAL CONTROL

MERCK PUTS UP TO $2.13 BILLION BEHIND SPR2015: CHINA ONCOLOGY LICENSING IS SHIFTING FROM “CHEAPER ASSETS” TO “EARLY INNOVATION”

MERCK–DAIICHI WITHDRAW I-DXD FILING: THE ERA WHEN A STRONG RESPONSE RATE WAS ENOUGH FOR AN ADC IS FADING

APOE4 AND BRAIN-VESSEL DAMAGE: ALZHEIMER’S MAY NEED TO BE TREATED BEYOND NEURONS AND AMYLOID

Facebook

Map

Online Members